Footnote

*CE marked for neurovascular access and removal/aspiration of emboli and thrombi from selected blood vessels in the neurovasculature. US FDA cleared to use in facilitating the insertion and guidance of microcatheters into selected blood vessels in the neurovasculature. 

Advancing stroke treatment

Innovative catheter technology that facilitates efficient vessel access and complete clot ingestion.* Footnote

INNOVATION

Scroll to Explore

References

(1) World Stroke Organisation www.world-stroke.org 2020

ABOUT ISCHEMIC STROKE

Stroke is a leading cause of death and adult disability. 1 References
Over 7 million people worldwide will have an ischemic stroke this year and more than 3 million people will die as a result. 1 References
Learn More

RESEARCH

References

(2) Nogueira et al. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. N. Engl. J. Med. 2016
(3) Goyal et al. Endovascular Thrombectomy after Large-Vessel Ischaemic Stroke: A Meta-Analysis of Individual Patient Data from Five Randomised Trials. The Lancet 2016

UNMET CLINICAL NEED

Despite recent clinical advances in stroke therapy, less than 50% of stroke patients treated today achieve a positive clinical outcome. 2,3 References
The need remains for a simple, repeatable solution to reperfuse occluded brain arteries.
Learn More

TECHNOLOGY

Video Button Icon Watch Full Video

THE SOLUTION

Learn More

Footnote

*CE marked for neurovascular access and removal/aspriation of emboli and thrombi from selected blood vessels in the neurovasculature. US FDA cleared to use in facilitating the insertion and guidance of microcatehters into selected blood vessels in the neurovasculature.

OUR COMPANY

Perfuze aims to improve patient outcomes with advanced superbore aspiration technology that simplifies access and clot removal.* Footnote
Located in Galway City in the West of Ireland, Perfuze was co-founded in 2018 by experienced medtech innovators, Wayne Allen and Liam Mullins.
The Team Careers

Knowledge